View more on these topics

Woolwich cuts fixed and tracker rates

Woolwich is cutting rates on its fixed and lifetime tracker mortgages and is introducing an LTV tier of 75%.

Fixed rates start at 5.54% for a three-year fixed deal and five and 10-year deals are both available at 5.64%.

These products are available up to a maximum 60% LTV, and carry a £995 fee.

Woolwich is also offering products on a maximum 75% LTV, including a three-year fixed rate at 5.84% and a two-year fixed deal at 5.99%.

Customers who are remortgaging under the Switch and Save package on products up to 85% LTV will also have their valuation and legal fees covered by Woolwich.

Changes to lifetime trackers include a fee-free product at base rate plus 0.94%, and a product with a £995 fee at base rate plus 0.64%.

Woolwich is also offering borrowers a drop-lock facility allowing customers to switch to a fixed rate at any time during the early repayment charge period. The minimum loan size for the fee-free lifetime tracker has been reduced from £100,000 to £50,000.

Andy Gray, head of mortgage at Woolwich, says: “With the drop-lock facility anyone taking a tracker with an early repayment charge will benefit from any base rate reductions, whilst having the flexibility to switch to a fixed rate to lock in when the opportunity is right.”

Recommended

Paradigm adds L&E to panel

Paradigm Mortgage Services hasadded London & European to its conveyancing panel. The move means Paradigm members now have access to L&E’s Complete Conveyancing product.

Lehmans plans to dump UK mortgage assets

Lehman Brothers is finalising a deal with BlackRock Financial to sell off the bulk of its UK residential mortgage assets, worth $4bn.

Embrace simplicity!

By Fiona Holmes, proposition communications manager When I first took out critical illness cover, I was overwhelmed. It wasn’t just the form filling, it was finding out about the sheer number of illnesses I was covered for. Did it give me peace of mind that I was covered for neuromyelitis optica or systematic lupus erythematosus? […]

Newsletter

News and expert analysis straight to your inbox

Sign up